Formulation and In-Vitro evaluation of mebeverine hydrochloride colon targetted micropellets for the treatment of irritable bowel syndrome

The present study in formulation and evaluation of Mebeverine hydrochloride micropellets. Mebeverine hydrochloride which is used as a anti spasmodic drug to treat irritable bowel syndrome. The pellets were prepared by pan coating powder layering method by using nonpareil seeds in core pellets and were coated with HPMC K4M, Eudragit S100 and Eudragit L100 in different ratios to form a film coat over the pellets. The prepared micropellets were evaluated with various evaluation methods such as drug content, loose surface crystal studies, in-vitro drug release studies, kinetic studies and stability studies as per ICH guidelines were performed. The formulated extended release micropellets were prepared by powder layering technique. In these formulations containing 20mg of Mebeverine hydrochloride and developed employing Eudragit L100, Eudragit S100 and HPMC K4M. The dissolution study of F7 formulation was concluded as the best formulation among other formulations, which showing the most desired drug release. It will be considered as optimized formulation. No significant change was observed in the drug content physical properties and dissolution rate of these micro pellets after the storage period of three months at 40±2oc and 75±5%RH.